We're excited to share that our Phase 2 study, JUNIPER, investigating the efficacy and safety of DAXXIFY® in adults with upper limb spasticity has just been published online in PM&R.
We would like to thank our collaborators, Atul Patel, MD, Michael Munin, Ziyad Ayyoub and Gerard Francisco, M.D. for their contributions to this work.
DAXXIFY® showed statistically significant improvements in score on the Modified Ashworth Scale (MAS), a tool used to measure the amount of excessive muscle tone, with a 500U dose. To learn more, please click to read the full publication: https://lnkd.in/ehEZWW3b
#DAXXIFY #UpperLimbSpasticity #Neurologists #RevanceScience #SettingtheNewStandard
Watch for Important Safety Information. For Full Prescribing Information, including Boxed Warning and Medication Guide, see https://lnkd.in/etBtYw-S
DAXXIFY® (daxibotulinumtoxinA-lanm) is a prescription medicine that is injected into muscles and used to treat cervical dystonia in adults. Ask your doctor to tell you about DAXXIFY®. DAXXIFY® may cause serious side effects hours to weeks after injection. Alert your doctor right away as difficulty swallowing, speaking, and breathing due to weakening of associated muscles can be a sign of a life-threatening condition. The most common side effects are headache, injection site pain, injection site redness, muscle weakness, and upper respiratory tract infection.